88 related articles for article (PubMed ID: 19564097)
1. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
[TBL] [Abstract][Full Text] [Related]
2. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
[TBL] [Abstract][Full Text] [Related]
3. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
[TBL] [Abstract][Full Text] [Related]
4. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
[TBL] [Abstract][Full Text] [Related]
5. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
[TBL] [Abstract][Full Text] [Related]
7. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
[TBL] [Abstract][Full Text] [Related]
8. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
[TBL] [Abstract][Full Text] [Related]
9. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
Chen YL; Chen KP; Chiu CC; Tai MH; Lung FW
BMC Psychiatry; 2018 Dec; 18(1):376. PubMed ID: 30509308
[TBL] [Abstract][Full Text] [Related]
10. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
[TBL] [Abstract][Full Text] [Related]
11. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
12. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
[TBL] [Abstract][Full Text] [Related]
13. Optimizing early prediction for antipsychotic response in schizophrenia.
Chang YC; Lane HY; Yang KH; Huang CL
J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
[TBL] [Abstract][Full Text] [Related]
14. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia.
Levine SZ; Leucht S
Schizophr Res; 2012 Nov; 141(2-3):168-72. PubMed ID: 22995933
[TBL] [Abstract][Full Text] [Related]
15. What does the PANSS mean?
Leucht S; Kane JM; Kissling W; Hamann J; Etschel E; Engel RR
Schizophr Res; 2005 Nov; 79(2-3):231-8. PubMed ID: 15982856
[TBL] [Abstract][Full Text] [Related]
16. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
17. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
18. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.
Lambert M; Schimmelmann BG; Naber D; Eich FX; Schulz H; Huber CG; Karow A
Pharmacopsychiatry; 2009 Nov; 42(6):277-83. PubMed ID: 19924588
[TBL] [Abstract][Full Text] [Related]
19. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
20. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.
Samara MT; Leucht C; Leeflang MM; Anghelescu IG; Chung YC; Crespo-Facorro B; Elkis H; Hatta K; Giegling I; Kane JM; Kayo M; Lambert M; Lin CH; Möller HJ; Pelayo-Terán JM; Riedel M; Rujescu D; Schimmelmann BG; Serretti A; Correll CU; Leucht S
Am J Psychiatry; 2015 Jul; 172(7):617-29. PubMed ID: 26046338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
